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Objective. To derive formulae to predict the likely 12-month health-related quality of life outcome following different
treatments for intermittent claudication (IC).
Design. A prospective, randomized, controlled study.
Materials. One hundred and seventy-one unselected patients with stable IC were sequentially randomized to invasive
therapy, supervised physical training or observation. Hierarchical analysis was used to identify significant predictors of
outcome.
Results. The strongest outcome predictors were baseline values of the respective outcome variables in all groups. No more
than two significant secondary predictors were identified for each outcome variable and no outcome variable was a predictor
of any other outcome variable. Resulting prediction equations achieved between 61 and 90% concordance with improvement
(75% considered adequate), with best prediction for invasive therapy and poorest for observation. Suggested cutpoints for the
various endpoints in the three groups had sensitivities ranging between 65 and 100% and false positive rates between 5 and
50%.
Conclusions. The derived equations adequately predicted improvement on the various outcome variables in invasive
therapy and supervised physical training, and may serve as aids in selecting patients likely to benefit most from a particular
treatment strategy. The uniqueness of the outcome variables underscores the importance of implementing a comprehensive
set of endpoints relevant to the impacts of the condition.
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Introduction
Intermittent claudication (IC) is a chronic disabling
condition that affects about 5% of the elderly popu-
lation1 – 3 and leads to significant impairment of health-
related quality of life (HRQL).1 – 14 As few patients
progress to critical limb ischaemia,15 – 18 the mainstay
of treatment is life-style modification and so-called
‘best medical therapy’.19 – 21 The role of adjuvant
therapies, such as supervised exercise and angioplasty
remain controversial.14,22 – 28 As such, it can be difficult
for clinicians to decide how best to manage individual
patients given limited resources. Most studies that
have attempted to identify outcome predictors,29 – 34
have focused on walking distance and not HRQL. The
aims of present study were to derive formulae
to predict the likely 12-month outcome following
different treatments for IC.
Patients and Methods
Two hundred and fifty-three consecutive patients
referred with a 6 months history of stable IC, and
who did not have a contraindication to surgery and/or
another disorder that would severely limit treadmill
walking, were sequentially randomized to control,
supervised exercise, or intervention groups, using a 21
variable algorithm.35,36 All patients were advised to
stop smoking and given risk factor advice. The control
group received no other treatment. The exercise group
attended classes in groups of 10–12 under the super-
vision of a physiotherapist. There were three 30-
minute sessions per week for 6 months and two
sessions per week thereafter. Patients were encour-
aged to train at home and some patients opted for
individualized programs. Patients in the intervention
group underwent an endovascular or open surgical
procedure depending on the results of angiography.
Patients randomized to the control or training groups
were allowed to undergo intervention if their ischae-
mia became severe.
Eur J Vasc Endovasc Surg 27, 24–32 (2004)
doi: 10.1016/S1078-5884(03)00352-6, available online at http://www.sciencedirect.com on
*Corresponding author. Dr Charles Taft, Health Care Research Unit,
Institute of Internal Medicine, Sahlgrenska University Hospital,
Go¨teborg University, Go¨teborg SE-413 45, Sweden.
1078–5884/03/000024 + 09 $35.00/0 q 2003 Published by Elsevier Ltd.
Baseline variables comprised age, gender, weight,
height, smoking habits, diabetes mellitus, creatinine,
cholesterol, triglycerides, haemoglobin, blood press-
ure, ankle and great toe pressure, exercise ECG,
dynamic spirometry, treadmill walking test and
occlusion plethysmography values before and after
exercise, groin pulses, symptom duration, income
source and dependency on home help.
At baseline and one year follow-up patients were
administered an extensive battery of generic and
study-specific questionnaires covering a wide spec-
trum of HRQL concepts. This study reports the results
from three instruments that in earlier analyses were
shown to be most sensitive to change in this patient
group.14 The Sickness Impact Profile IC (SIPIC) scale
comprises 12 items: ambulation, home management,
social interaction, mobility, alertness behavior and
sleep and rest.3,37 – 39 The General Health Rating Index-
Current Health (GHRI-CH) is a measure of perceived
current health status and comprises nine items which
are rated against 4-step scales from definitely false to
definitely true. Ratings are summed to give a single
score. Higher scores are indicative of better-perceived
health status.40 The Symptoms and Complaints scale is
a study-specific instrument comprising 9 items
(Appendix A).
Outcome predictors, prediction equations and
probabilities of outcome success associated with
observed values were derived and illustrated using a
six-stage hierarchical analysis.
1. Correlations between every baseline and outcome
variable were calculated with Pitman’s permu-
tation test.41 Those that were significant were
selected as potential predictors.
2. Pitman correlations between potential predictor
variables were calculated.
3. For variables correlating significantly with each
other, their relative strength as potential predictors
was elicited by partial correlations with Mantel’s
test.42
4. The resulting variables from the previous steps
were entered as covariates in a multivariate
regression analyses to obtain estimates of the
proportion of the variance in the outcome variable
accounted for by the model.
5. Logistic regression analyses were performed using
the derived regression models to predict one-year
outcome in variables dichotomized as improved
versus no-change/deteriorated.
6. Lastly, observed values and associated probabilities
of successful outcome were represented in Receiver
Operating Characteristic (ROC) curves. The area
under the curve (AUC) may be interpreted as a
weighted average of the degree of prediction the
model provides over its entire score range, where
perfect prediction is indicated by an AUC value of
1.0 and no prediction by an AUC of 0.50. The
criteria used for selecting cut-off points were that
sensitivity exceeded 60% and that false positive rate
was less than half the sensitivity.
Results
There were no significant differences in baseline
characteristics between 25 patients who declined,
and those who agreed, to complete the study. At 12
months, data were available in 171 patients (66% male)
of mean (SD) age 67 (8.3) years because 30 died, nine
underwent amputations and 18 were lost to follow-up.
These patients had significantly better SIP sleep and
rest scores than the other 57 patients. There were 65, 48
and 58 patients in the control, supervised exercise and
intervention groups, respectively. Results are only
presented where predictors explained at least 20% of
the variance in outcome and where AUCs were greater
than 0.75.
Treatment success was defined as an improvement,
irrespective of degree, over baseline values. No
treatment achieved a 100% success in terms of any
outcome variable (Table 1). The intervention group
had the highest proportion of improved patients.
Walk symptoms
Invasive treatment. Analyses produced three significant
predictors of change in walk symptoms: walk
symptoms, exercise ECG and groin pulse (Table 2).
Change in walk distance correlated negatively with
baseline walk symptoms and groin pulse and
positively with exercise ECG. The regression model
accounted for 47% of the variance and the logistic
Table 1. Treatment success rates. Percent of treatment groups showing improvement on each outcome variable at one-year follow-up.
Group N Walk symptoms Rest symptoms SIPIC GHRI
Invasive treatment 58 79 53 64 86
Supervised training 48 38 50 40 48
Controls 65 45 39 37 50
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regression achieved 87% concordance in predicting
improvement. Fig. 1(a) shows the ROC curve expres-
sing the relationship between the true positive rate
and the false positive rate for each observed value
obtained from the regression equation. The optimal
cut-off point for screening of candidates potentially
deriving benefit in terms of walk symptoms from
invasive treatment appears to be 1.89 (71% sensitivity,
9% false positive rate and 74% overall accuracy).
Supervised physical training. Significant baseline
predictors of change in walk symptoms were walking
distance and toe pressure (Table 2). A significant
negative correlation was found with baseline walk
symptoms and a positive correlation with toe press-
ure. The regression model explained 40% of the
variance and the logistic regression model achieved
79% concordance. Fig. 1(b) shows the ROC curve for
the regression equation. The optimal cut-off point
appears to be 20.15 (67% sensitivity, 17% false
positive rate and 77% accuracy).
Rest symptoms
Invasive treatment. Rest symptoms at baseline was the
only significant predictor of change in rest symptoms
(negative correlation) (Table 3). The regression model
accounted for 43% of the variance in 1-year change in
rest symptoms. The logistic regression model achieved
81% concordance. Fig. 2(a) shows the ROC curve for
observed values obtained from the regression
equation. The optimal appears to be 20.52 (100%
sensitivity, 38% false positive rate and 76% accuracy).
Supervised physical training. A significant negative
correlation was found for baseline rest symptoms
(Table 3). The regression model explained 30% of the
variance and the logistic regression model achieved
86% concordance. The optimal cutpoint shown in Fig.
2(b) appears to be 0.58 (68% sensitivity, 15% false
positive rate and 77% accuracy).
Sickness Impact Profile Intermittent Claudication scale
(SIPIC)
Invasive treatment. There was one significant predictor
of change in SIPIC: baseline SIPIC (negative correlation)
(Table 4). The regression model accounted for 35% of
the variance in 1-year change in SIPIC. The logistic
regression model yielded 79% concordance. The
optimal cut-off point for the obtained values (Fig. 3)
appears to be 1.28 (69% sensitivity, 16% false positive
rate and 74% accuracy rate).Ta
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General Health Rating Index-Current Health (GHRI-CH)
Invasive treatment. Three significant predictors were
identified: GHRI-CH at baseline (negative correlation),
creatinine (negative) and ECG (negative) (Table 5). The
regression model accounted for 37% of the variance.
The logistic regression model achieved 90% concor-
dance in predicting improvement. The optimal cut-off
point for observed values obtained from the regression
equation (Fig. 4(a)) appears to be 2.26 (72% sensitivity,
0% false positive rate and 73% accuracy).
Supervised physical training. Significant baseline
predictors of change in GHRI-CH were baseline
GHRI-CH (negative correlation), cholesterol (positive)
and ankle pressure (negative) (Table 5). The regression
model explained 22% of the variance and the logistic
regression model produced 77% concordance. The
optimal cut-off point appears to be 0.08, with 78%
Fig. 1. Walk symptoms. Receiver operating curves (ROC) for walk symptoms in the invasive therapy group and the
supervised physical traing group, respectively. Plotted values are derived from the regression equations shown in the figures,
where walk ¼ walk symptoms, groin ¼ groin pressure, ECGreak ¼ exercise ECG. Area under the curves (AUC), indicating
the overall degree of prediction of the model, is given in the figures.
Fig. 2. Rest symptoms. Receiver operating curves (ROC) for rest symptoms in the invasive therapy group and the supervised
physical traing group, respectively. Plotted values are derived from the regression equations shown in the figures, where
REST ¼ rest symptoms. Area under the curves (AUC), indicating the overall degree of prediction of the model, is given in the
figures.
IC Outcome Predictors 27
Eur J Vasc Endovasc Surg Vol 27, January 2004
Table 3. Rest symptoms. Performance of derived prediction equations in predicting one-year improvement in the invasive treatment and supervised training groups.
Treatment group % Improved Predictors % Variance Regression equation % Concordance Optimal cutpoint % Sensitivity, false positive, accurate
Invasive treatment 53 Rest symptoms 43 22.453 þ 1.682 RS 83 20.52 100, 38, 76
Supervised training 50 Rest symptoms 30 25.272 þ 3.253 RS 86 0.58 68, 15, 77
Table 4. Sickness Impact Profile Intermittent claudication. Performance of derived prediction equations in predicting one-year improvement in the invasive treatment group.
Treatment group % Improved Predictors % Variance Regression equation % Concordance Optimal cutpoint % Sensitivity, false positive, accurate
Invasive treatment 64 SIPIC 35 21.196 þ 0.619 SIPIC 83 1.28 69, 16, 74
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sensitivity, 30% false positive rate and 73% accuracy
(Fig. 4(b)).
Discussion
Traditionally, conservative management was advo-
cated for claudicants with mild-to-moderate symp-
toms, while interventional treatment was confined to
patients with only the most severe symptoms. How-
ever, the relative effectiveness of conservative versus
interventional therapy remains controversial and it
can be difficult to predict how individual patients will
respond. Although many previous studies have
attempted to identify predictors of outcome, the
present study is unique in that the patients were
relatively unselected, randomized to one of three
treatment strategies, followed prospectively for one
year and were assessed by means of patient-focused
outcomes.
Success rates were highest in the intervention
group, while supervised training and conservative
treatments produced similar results. However, no
treatment modality achieved 100% success rate on
any outcome variable at one year after treatment.
In order to identify significant baseline predictors of
patient improvement at one year an hierarchical
analysis procedure was used. Of these, a maximum
of three of 30 baseline variables qualified as significant,
independent predictors of any single outcome variable
Fig. 3. Sickness Impact Profile Intermittent Claudication.
Receiver operating curves (ROC) for SIPIC in the invasive
therapy group. Plotted values are derived from the
regression equations shown in the figures. Area under the
curves (AUC), indicating the overall degree of prediction of
the model, is given in the figures.
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for each treatment. A major finding in this study was
that, independent of treatment modality, the strongest
predictors of treatment outcome were baseline values
of the respective outcome measures used, where
poorer baseline values were associated with improved
outcome. The latter result is consistent with three
earlier studies,13,26,43 but contradicts the results from
another.44 The low response rate (63%) obtained in the
last study may have biased those results. Furthermore,
no baseline values of any other outcome variable
explained a significant proportion of the variance in
outcome variables at one year, indicating the unique-
ness of the study endpoints. This uniqueness under-
scores the importance of implementing a
comprehensive set of endpoints relevant to the
impacts of the condition.
Age has previously been found to predict walking
performance in training programs.21 However, in our
study age predicted walking performance only in the
invasive treatment group (data not shown) and was
not a predictor of any other outcome. Given that
claudicants are a relatively homogeneous group with
respect to age, it is perhaps surprising that age predicts
outcome at all. Further research is needed to deter-
mine the varying impacts of age on treatment
outcomes.
In light of the demonstrated risks associated with
smoking and benefits prescribed smoking cessation,
an unexpected result in this study was that smoking
cessation was not a significant predictor of outcome. A
possible reason for this is that since all patients were
strongly encouraged to quit smoking, those who did
not comply responded in a socially desirable manner.
In fact, in a sub-sample of patients for whom blood
nicotine levels were available, many patients had
nicotine concentrations inconsistent with self-reported
smoking cessation.
The ROC curves presented here allow comparison
of obtained patient values with our observed values
and associated sensitivities and false positive rates.
Based on such comparisons the clinician may estimate
the probability of a patient achieving successful
treatment outcome in a variety of areas impacted on
by the disease. Such estimates may aid both in
consultations with patients by providing them realistic
expectations of treatment success from a patient
perspective and in clinical decision making by allow-
ing comparisons of success probabilities for any one
treatment option. The suggested cut-off points have
been provided only as rough guidelines for dis-
tinguishing the values above which outcome discrimi-
nation accuracy is poor (the upper extreme of the
curve categorizes all cases as improved, i.e. 100%
sensitivity and 100% false positive rate). The choice of
a cut-off for predicting improvement is difficult
because of the implicit trade-offs between sensitivity
and specificity. The decision naturally depends on the
implications of either missing patients who may
actually improve or misclassifying patients who may
not. ROC curves illustrate the trade-off for each
obtained value and ideally allow the practitioner to
choose the most appropriate cut-off, weighing in the
Fig. 4. General Health Rating Index - Current Health. Receiver operating curves (ROC) for GHRI-CH in the invasive therapy
group and the supervised physical training group, respectively. Plotted values are derived from the regression equations
shown in the figures, where GH ¼ General Health Rating Index-Current Health and ECGreac ¼ exercise ECG. Area under
the curves (AUC), indicating the overall degree of prediction of the model, is given in the figures.
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risks involved for his particular patient. The ROC
curves thus offer the advantage of permitting the
clinician him/herself to select the level of accuracy
he/she deems suitable.
It is important to note that we applied minimum
standards for defining treatment success, i.e. any
improvement on the endpoints, however, slight. In
other words, our results do not take into consideration
the degree of improvement/deterioration in outcome
variables nor do they imply any criteria for what may
be considered clinically significant improvement. This
naturally imposes limits on the interpretation and
application of our results, however, in the absence of
established yardsticks for measuring how much
improvement corresponds to success from the
patient’s perspective we opted for this minimum
standard.
Caution should also be exercised in interpreting our
results due the size of our study sample ðn ¼ 171Þ:
Subgroup analyses thus were performed on samples
comprising between 48 and 65 patients. In an attempt
to compensate for small sample sizes fairly stringent
criteria were applied in defining prediction adequacy,
i.e. explained variance . 0.20 and AUC . 0.75. Appli-
cation of these criteria precluded prediction in the
observation group on all four outcome measures and
in the exercise training group on one measure. Larger
and longer-term cohort studies should be performed
to cross-validate the equations to determine their
generalizability.
In summary, we suggest that the prediction of
treatment outcome can be enhanced by the use of these
equations in combination with the probabilities of
treatment success associated with obtained values
(ROC curves). Such information may be helpful in
selecting patients for treatments and in patient
consultations. Their predictive power can possibly be
improved by adding other correlates of the outcome
variables to the models than those studied as well as
by collecting additional patient data.
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Appendix Symptoms and complaints scale
Patients sometimes say that they have the following
problems. Please indicate to what extent you have
experienced these problems during the past week.
Mark the box under the response choice that best
applies to you (Table A1).
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